• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Learnings From the Graveyard of Phase 2 and 3 Nonalcoholic Steatohepatitis Trials.

作者信息

Francque Sven M, Noureddin Mazen, Krag Aleksander

机构信息

Department of Gastroenterology Hepatology, Antwerp University Hospital, Edegem, Belgium; InflaMed Centre of Excellence, Laboratory for Experimental Medicine and Paediatrics, Translational Sciences in Inflammation and Immunology, Faculty of Medicine and Health Sciences, University of Antwerp, Wilrijk, Belgium.

Houston Research Institute, Houston, Texas; Houston Methodist Hospital, Houston, Texas.

出版信息

Clin Gastroenterol Hepatol. 2024 Jan;22(1):16-19. doi: 10.1016/j.cgh.2023.07.013. Epub 2023 Jul 28.

DOI:10.1016/j.cgh.2023.07.013
PMID:37517632
Abstract
摘要

相似文献

1
Learnings From the Graveyard of Phase 2 and 3 Nonalcoholic Steatohepatitis Trials.来自非酒精性脂肪性肝炎2期和3期试验失败案例的经验教训。
Clin Gastroenterol Hepatol. 2024 Jan;22(1):16-19. doi: 10.1016/j.cgh.2023.07.013. Epub 2023 Jul 28.
2
Nonalcoholic Steatohepatitis (NASH) and Hepatic Fibrosis: Emerging Therapies.非酒精性脂肪性肝炎（NASH）和肝纤维化：新兴疗法。
Annu Rev Pharmacol Toxicol. 2018 Jan 6;58:649-662. doi: 10.1146/annurev-pharmtox-010617-052545. Epub 2017 Oct 20.
3
Nonalcoholic steatohepatitis (NASH) cirrhosis: a snapshot of therapeutic agents in clinical development and the optimal design for clinical trials.非酒精性脂肪性肝炎（NASH）肝硬化：临床开发中治疗药物的快照及临床试验的最佳设计。
Expert Opin Investig Drugs. 2022 Feb;31(2):163-172. doi: 10.1080/13543784.2022.2032640. Epub 2022 Feb 10.
4
Current Options and Future Directions for NAFLD and NASH Treatment.非酒精性脂肪性肝病和非酒精性脂肪性肝炎治疗的现有选择和未来方向。
Int J Mol Sci. 2021 Jul 15;22(14):7571. doi: 10.3390/ijms22147571.
5
[Machanism and intervention of nonalcoholic steatohepatitis-associated fibrosis].[非酒精性脂肪性肝炎相关纤维化的机制与干预]
Zhonghua Gan Zang Bing Za Zhi. 2019 Jun 20;27(6):415-419. doi: 10.3760/cma.j.issn.1007-3418.2019.06.005.
6
Cenicriviroc for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis: AURORA Phase 3 study design.西尼riviroc 治疗非酒精性脂肪性肝炎成人肝纤维化：AURORA 期 3 研究设计。
Contemp Clin Trials. 2020 Feb;89:105922. doi: 10.1016/j.cct.2019.105922. Epub 2019 Dec 24.
7
Designing an exploratory phase 2b platform trial in NASH with correlated, co-primary binary endpoints.设计 NASH 探索性 2b 平台试验，关联、共同主要的二元终点。
PLoS One. 2023 Mar 9;18(3):e0281674. doi: 10.1371/journal.pone.0281674. eCollection 2023.
8
Emerging Treatments for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis.非酒精性脂肪性肝病和非酒精性脂肪性肝炎的新兴治疗方法。
Clin Liver Dis. 2018 Feb;22(1):189-199. doi: 10.1016/j.cld.2017.08.013. Epub 2017 Oct 10.
9
Structure of proof of concept studies that precede a nonalcoholic steatohepatitis development program.非酒精性脂肪性肝炎研发项目之前的概念验证研究结构。
Clin Pharmacol Ther. 2017 Apr;101(4):444-446. doi: 10.1002/cpt.560. Epub 2016 Dec 29.
10
REGENERATE: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis.REGENERATE 研究：一项关键性、随机、3 期研究的设计，旨在评估奥贝胆酸在非酒精性脂肪性肝炎纤维化患者中的安全性和疗效。
Contemp Clin Trials. 2019 Sep;84:105803. doi: 10.1016/j.cct.2019.06.017. Epub 2019 Jun 29.

引用本文的文献

1
Gradual DNA methylation changes reveal transcription factors implicated in metabolic dysfunction-associated steatotic liver disease progression and epigenetic age acceleration.逐渐发生的DNA甲基化变化揭示了与代谢功能障碍相关的脂肪性肝病进展和表观遗传年龄加速有关的转录因子。
Clin Epigenetics. 2025 Aug 4;17(1):138. doi: 10.1186/s13148-025-01945-6.
2
Inhibition of intrahepatic monocyte recruitment by Cenicriviroc and extracellular matrix degradation by MMP1 synergistically attenuate liver inflammation and fibrogenesis in vivo.西尼riviroc 抑制肝内单核细胞募集和 MMP1 降解细胞外基质协同减轻体内肝脏炎症和纤维化。
Sci Rep. 2024 Jul 23;14(1):16897. doi: 10.1038/s41598-024-67926-6.